18.8 C
New York
Sunday, September 25, 2022

COMPASS Pathways (CMPS) to Release Earnings on Tuesday



COMPASS Pathways (NASDAQ:CMPSGet Rating) is scheduled to post its quarterly earnings results before the market opens on Tuesday, May 10th. Analysts expect COMPASS Pathways to post earnings of ($0.68) per share for the quarter.

COMPASS Pathways (NASDAQ:CMPSGet Rating) last posted its earnings results on Thursday, February 24th. The company reported ($0.61) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.13). During the same period in the previous year, the company posted ($0.52) EPS. On average, analysts expect COMPASS Pathways to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Shares of NASDAQ:CMPS traded down $0.49 during trading on Wednesday, reaching $9.08. The company had a trading volume of 603 shares, compared to its average volume of 257,793. The firm’s fifty day moving average is $12.55 and its 200 day moving average is $20.96. The firm has a market capitalization of $381.54 million, a PE ratio of -5.10 and a beta of 3.11. COMPASS Pathways has a twelve month low of $9.06 and a twelve month high of $49.51.

In other news, Director David Y. Norton sold 3,384 shares of the stock in a transaction on Tuesday, March 29th. The shares were sold at an average price of $12.48, for a total transaction of $42,232.32. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Ekaterina Malievskaia sold 6,372 shares of the company’s stock in a transaction on Tuesday, March 29th. The stock was sold at an average price of $12.48, for a total transaction of $79,522.56. The disclosure for this sale can be found here.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. JPMorgan Chase & Co. boosted its holdings in shares of COMPASS Pathways by 1,812.3% during the 4th quarter. JPMorgan Chase & Co. now owns 3,098 shares of the company’s stock worth $69,000 after buying an additional 2,936 shares during the period. UBS Group AG boosted its holdings in shares of COMPASS Pathways by 31.7% during the 3rd quarter. UBS Group AG now owns 3,777 shares of the company’s stock worth $114,000 after buying an additional 910 shares during the period. Royal Bank of Canada boosted its holdings in shares of COMPASS Pathways by 21.3% during the 3rd quarter. Royal Bank of Canada now owns 8,066 shares of the company’s stock worth $240,000 after buying an additional 1,418 shares during the period. Geode Capital Management LLC boosted its holdings in shares of COMPASS Pathways by 34.8% during the 3rd quarter. Geode Capital Management LLC now owns 9,295 shares of the company’s stock worth $277,000 after buying an additional 2,400 shares during the period. Finally, LPL Financial LLC bought a new stake in shares of COMPASS Pathways during the 4th quarter worth $234,000. 17.86% of the stock is owned by institutional investors and hedge funds.

A number of analysts have recently weighed in on CMPS shares. Zacks Investment Research raised shares of COMPASS Pathways from a “sell” rating to a “hold” rating in a research note on Monday. Canaccord Genuity Group reduced their price target on shares of COMPASS Pathways from $80.00 to $78.00 and set a “buy” rating for the company in a research note on Monday, February 28th. One equities research analyst has rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, COMPASS Pathways has an average rating of “Buy” and an average target price of $74.89.

About COMPASS Pathways (Get Rating)

COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that has completed Phase IIb clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder.

Recommended Stories

Earnings History for COMPASS Pathways (NASDAQ:CMPS)



Receive News & Ratings for COMPASS Pathways Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for COMPASS Pathways and related companies with MarketBeat.com’s FREE daily email newsletter.



Source link

Related Articles

Stay Connected

0FansLike
3,498FollowersFollow
0SubscribersSubscribe

Latest Articles